Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Molecular profile-directed chemotherapy in metastatic HER2(-) esophagogastric adenocarcinoma
NCT02358863Terminated
- Sponsor
- Georgetown University
- Start
- Feb 2015
- Primary completion
- Nov 2016
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Open-label trial of oxaliplatin, fluorouracil, folinic acid, docetaxel, capecitabine and 3 more in Esophago-Gastric Adenocarcinoma, sponsored by Georgetown University. Started Feb 2015; status: terminated.
02
Drugs
oxaliplatinfluorouracilfolinic aciddocetaxelcapecitabine
03
Conditions
Esophago-Gastric Adenocarcinoma
Beyond the preview
Go deeper on NCT02358863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02358863.